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  Evidence-based answer
Evidence is confl icting with regard to 
the comparative frequency of venous 
thrombolic events (VTE) among women 
using the transdermal patch when 
compared to an oral contraceptive (OC), 
even though the patch produces a relatively 
high serum ethinyl estradiol (EE) level 
(strength of recommendation [SOR]: C, 
confl icting cohort case-control studies). 
 The vaginal ring has a risk of VTE 
comparable to that of an OC (SOR: B, 
1 comparative study).
Clinical commentary
For now, base decisions 
on patient preference 
This review points out that we don’t 
have enough evidence to make a strong 
recommendation about oral or nonoral 
estrogen-containing contraceptives based 
on the risk of thromboembolic disease. All 
estrogen-containing contraceptives have 
similar side-effect profi les, regardless of the 
route of administration. 
 In my experience, the patch or 
ring appeals to women who have had 
diffi culty with OCs and need a simpler 
dosing regimen to improve compliance. 
The choice between an oral estrogen-
containing contraceptive and the patch 
or ring should be based on the patient’s 
preference, not the risk of thromboembolic 
disease, until we have evidence to suggest 
otherwise.
Richard Williams, MD
University of Nevada School of Medicine, Reno
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All estrogen-
containing 
contraceptives 
have similar side-
effect proﬁ les, 
regardless of the 
route of 
administration ❚ Evidence summary
Two nonoral estrogen-progestin contra-
ceptives have been approved by the US 
Food and Drug Administration (FDA). 
OrthoEvra is a transdermal patch ap-
plied weekly for 3 consecutive weeks, 
followed by 1 patch-free week per cycle.1 
The NuvaRing is a vaginal ring worn for 
3 consecutive weeks in a 4-week cycle.2 
The patch causes greater estrogen 
exposure than OCs or the ring
In November 2005, the FDA issued an 
update to the labeling of the Ortho-
Evra contraceptive patch, reporting 
increased systemic estrogen exposure, 
which may increase the risk of blood 
clots.3 The FDA warned that the trans-
dermal patch exposes the user to 60% 
more estrogen than the typical birth 
control pill containing 35 μg EE.3 In 
January 2008, the FDA approved an 
additional update to include the results 
of a new study that found users of the 
patch to be at higher risk of developing 
VTE than OC users.3,4
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One pharmacokinetic study found that 
exposure to EE differed among delivery sys-
tems. The area under the EE concentration-
vs-time curve in the patch group was 1.6 
times higher than in the OC group (P<.05) 
and 3.4 times higher than in the vaginal ring 
group (P<.05).2 
So what’s the VTE risk? Two 
studies, contrasting conclusions
A nested case-control study—based on a Phar-
Metrics longitudinal database of informa-
tion from paid claims by managed care health 
plans—included 215,769 women between the 
ages of 15 and 44 years who had started using 
the patch or a norgestimate-EE combination 
OC since April 1, 2002, when OrthoEvra was 
fi rst introduced on the US market.5 Investiga-
tors identifi ed 68 diagnosed cases of VTE with 
no identifi able risk factors.
The overall incidence of VTE in this study 
was 52.8 per 100,000 women-years (95% 
confi dence interval [CI], 35.8-74.9) among 
patch users and 41.8 per 100,000 women-
years among OC users (95% CI, 29.4-57.6).5 
The study concluded that the risk of nonfatal 
VTE for the patch isn’t higher than the risk for 
an OC containing 35 μg EE and norgestimate 
(odds ratio [OR]=0.9; 95% CI, 0.5-1.6; inci-
dence rate ratio [IRR]=1.1; 95% CI, 0.7-1.8). 
A recent update to the study evaluated an 
additional 17 months of data on new cases of 
women meeting the same criteria. The supple-
mentary results proved consistent with earlier 
conclusions, indicating that the risk of nonfatal 
VTE for the patch is similar to the risk for the 
OC (OR=1.1; 95% CI, 0.6-2.1).6 Combined 
data from the original study and the update 
show that the OR for VTE is 1.0 (95% CI, 0.7-
1.5) in users of the patch compared with users 
of the OC. 6
Another nested case-control study—based 
on UnitedHealthcare insurance claims data 
and confi rmatory chart reviews—showed con-
trasting results. The study included 340,377 
women between the ages of 15 and 44 years 
who were new users of the patch or new and 
previous users of a norgestimate-EE combi-
nation OC from April 1, 2002 through De-
cember 31, 2004.3 Investigators verifi ed 57 
diagnoses of VTE, controlling for confound-
VTE risk
treatment and consider tapering Effexor XR in the third trimester. Labor, Delivery, Nursing—The effect on labor and
delivery in humans is unknown. Venlafaxine and ODV have been reported to be excreted in human milk. Because of the
potential for serious adverse reactions in nursing infants from Effexor XR, a decision should be made whether to
discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric
Use—Safety and effectiveness in the pediatric population have not been established (see BOX WARNING and
WARNINGS: Clinical Worsening and Suicide Risk). No studies have adequately assessed the impact of Effexor XR
on growth, development, and maturation of children and adolescents. Studies suggest Effexor XR may adversely affect
weight and height (see PRECAUTIONS-General, Changes in Height and Changes in Weight ). Should the decision be made
to treat a pediatric patient with Effexor XR, regular monitoring of weight and height is recommended during treatment,
particularly if long term. The safety of Effexor XR for pediatric patients has not been assessed for chronic treatment >6
months. In studies in patients aged 6-17, blood pressure and cholesterol increases considered to be clinically relevant
were similar to that observed in adult patients. The precautions for adults apply to pediatric patients. Geriatric Use—No
overall differences in effectiveness or safety were observed between geriatric and younger patients. Greater sensitivity
of some older individuals cannot be ruled out. SSRIs and SNRIs, including Effexor XR, have been associated with
cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event
(see PRECAUTIONS: Hyponatremia). ADVERSE REACTIONS: Associated with Discontinuation of Treatment—
The most common events leading to discontinuation in MDD, GAD, SAD, and PD trials included nausea, anorexia, anxiety,
impotence, dry mouth, dizziness, insomnia, somnolence, hypertension, diarrhea, paresthesia, tremor, abnormal (mostly
blurred) vision, abnormal (mostly delayed) ejaculation, asthenia, vomiting, nervousness, headache, vasodilatation,
thinking abnormal, decreased libido, and sweating. Commonly Observed Adverse Events in Controlled Clinical Trials
for MDD, GAD, SAD, and PD—Body as a Whole: asthenia, headache, flu syndrome, accidental injury, abdominal pain.
Cardiovascular: vasodilatation, hypertension, palpitation. Digestive: nausea, constipation, anorexia, vomiting, flatulence,
diarrhea, eructation. Metabolic/Nutritional: weight loss. Nervous System: dizziness, somnolence, insomnia, dry mouth,
nervousness, abnormal dreams, tremor, depression, hypertonia, paresthesia, libido decreased, agitation, anxiety,
twitching. Respiratory System: pharyngitis, yawn, sinusitis. Skin: sweating. Special Senses: abnormal vision. Urogenital
System: abnormal ejaculation, impotence, orgasmic dysfunction (including anorgasmia) in females. Vital Sign Changes:
Effexor XR was associated with a mean increase in pulse rate of about 2 beats/min in depression and GAD trials and a
mean increase in pulse rate of 3 beats/min in SAD trials. (see Sustained Hypertension and Elevations in Systolic and
Diastolic Blood Pressure sections of WARNINGS). Laboratory Changes: Clinically relevant increases in serum
cholesterol were noted in Effexor XR clinical trials. Increases were duration dependent over the study period and tended
to be greater with higher doses. Other Events Observed During the Premarketing Evaluation of Effexor and Effexor XR
—N=7,212. “Frequent”=events occurring in at least 1/100 patients; “infrequent”=1/100 to 1/1000 patients;
“rare”=fewer than 1/1000 patients. Body as a whole - Frequent: chest pain substernal, chills, fever, neck pain;
Infrequent: face edema, intentional injury, malaise, moniliasis, neck rigidity, pelvic pain, photosensitivity reaction, suicide
attempt, withdrawal syndrome; Rare: appendicitis, bacteremia, carcinoma, cellulitis, granuloma.  Cardiovascular
system - Frequent: migraine, tachycardia; Infrequent: angina pectoris, arrhythmia, extrasystoles, hypotension, peripheral
vascular disorder (mainly cold feet and/or cold hands), postular hypotension, syncope; Rare: aortic aneurysm, arteritis,
first-degree atrioventricular block, bigeminy, bundle branch block, capillary fragility, cerebral ischemia, coronary artery
disease, congestive heart failure, heart arrest, hematoma, cardiovascular disorder (mitral valve and circulatory
disturbance), mucocutaneous hemorrhage, myocardial infarct, pallor, sinus arrhythmia, thrombophlebitis. Digestive
system - Frequent: increased appetite; Infrequent: bruxism, colitis, dysphagia, tongue edema, eructation, esophagitis,
gastritis, gastroenteritis, gastrointestinal ulcer, gingivitis, glossitis, rectal hemorrhage, hemorrhoids, melena, oral
moniliasis, stomatitis, mouth ulceration; Rare: abdominal distension, biliary pain, cheilitis, cholecystitis, cholelithiasis,
esophageal spasms, duodenitis, hematemesis, gastroesophageal reflux disease, gastrointestinal hemorrhage, gum
hemorrhage, hepatitis, ileitis, jaundice, intestinal obstruction, liver tenderness, parotitis, periodontitis, proctitis, rectal
disorder, salivary gland enlargement, increased salivation, soft stools, tongue discoloration. Endocrine system - Rare:
galactorrhoea, goiter, hyperthyroidism, hypothyroidism, thyroid nodule, thyroiditis. Hemic and lymphatic system -
Frequent: ecchymosis; Infrequent: anemia, leukocytosis, leukopenia, lymphadenopathy, thrombocythemia; Rare:
basophilia, bleeding time increased, cyanosis, eosinophilia, lymphocytosis, multiple myeloma, purpura,
thrombocytopenia. Metabolic and nutritional - Frequent: edema, weight gain; Infrequent: alkaline phosphatase
increased, dehydration, hypercholesteremia, hyperglycemia, hyperlipidemia, hypokalemia, SGOT increased, SGPT
increased, thirst; Rare: alcohol intolerance, bilirubinemia, BUN increased, creatinine increased, diabetes mellitus,
glycosuria, gout, healing abnormal, hemochromatosis, hypercalcinuria, hyperkalemia, hyperphosphatemia,
hyperuricemia, hypocholesteremia, hypoglycemia, hyponatremia, hypophosphatemia, hypoproteinemia, uremia.
Musculoskeletal system - Infrequent: arthritis, arthrosis, bone spurs, bursitis, leg cramps, myasthenia, tenosynovitis;
Rare: bone pain, pathological fracture, muscle cramp, muscle spasms, musculoskeletal stiffness, myopathy,
osteoporosis, osteosclerosis, plantar fasciitis, rheumatoid arthritis, tendon rupture. Nervous system - Frequent: amnesia,
confusion, depersonalization, hypesthesia, thinking abnormal, trismus, vertigo; Infrequent: akathisia, apathy, ataxia,
circumoral paresthesia, CNS stimulation, emotional lability, euphoria, hallucinations, hostility, hyperesthesia, hyperkinesia,
hypotonia, incoordination, libido increased, manic reaction, myoclonus, neuralgia, neuropathy, psychosis, seizure,
abnormal speech, stupor, suicidal ideation; Rare: abnormal/changed behavior, adjustment disorder, akinesia, alcohol
abuse, aphasia, bradykinesia, buccoglossal syndrome, cerebrovascular accident, feeling drunk, loss of consciousness,
delusions, dementia, dystonia, energy increased, facial paralysis, abnormal gait, Guillain-Barré syndrome, homicidal
ideation, hyperchlorhydria, hypokinesia, hysteria, impulse control difficulties, motion sickness, neuritis, nystagmus,
paranoid reaction, paresis, psychotic depression, reflexes decreased, reflexes increased, torticollis. Respiratory system
- Frequent: cough increased, dyspnea; Infrequent: asthma, chest congestion, epistaxis, hyperventilation, laryngismus,
laryngitis, pneumonia, voice alteration; Rare: atelectasis, hemoptysis, hypoventilation, hypoxia, larynx edema, pleurisy,
pulmonary embolus, sleep apnea. Skin and appendages - Frequent: pruritus; Infrequent: acne, alopecia, contact
dermatitis, dry skin, eczema, maculopapular rash, psoriasis, urticaria; Rare: brittle nails, erythema nodosum, exfoliative
dermatitis, lichenoid dermatitis, hair discoloration, skin discoloration, furunculosis, hirsutism, leukoderma, miliaria, petechial
rash, pruritic rash, pustular rash, vesiculobullous rash, seborrhea, skin atrophy, skin hypertrophy, skin striae, sweating
decreased. Special senses - Frequent: abnormality of accommodation, mydriasis, taste perversion; Infrequent:
conjunctivitis, diplopia, dry eyes, eye pain, otitis media, parosmia, photophobia, taste loss; Rare: blepharitis, cataract,
chromatopsia, conjunctival edema, corneal lesion, deafness, exophthalmos, eye hemorrhage, glaucoma, retinal
hemorrhage, subconjunctival hemorrhage, hyperacusis, keratitis, labyrinthitis, miosis, papilledema, decreased pupillary
reflex, otitis externa, scleritis, uveitis, visual field defect. Urogenital system - Frequent: albuminuria, urination impaired;
Infrequent: amenorrhea, cystitis, dysuria, hematuria, kidney calculus, kidney pain, leukorrhea, menorrhagia, metrorrhagia,
nocturia, breast pain, polyuria, pyuria, prostatic disorder (prostatitis, enlarged prostate, and prostate irritability), urinary
incontinence, urinary retention, urinary urgency, vaginal hemorrhage, vaginitis; Rare: abortion, anuria, balanitis, bladder
pain, breast discharge, breast engorgement, breast enlargement, endometriosis, female lactation, fibrocystic breast,
calcium crystalluria, cervicitis, orchitis, ovarian cyst, prolonged erection, gynecomastia (male), hypomenorrhea, kidney
function abnormal, mastitis, menopause, pyelonephritis, oliguria, salpingitis, urolithiasis, uterine hemorrhage, uterine
spasm, vaginal dryness. Postmarketing Reports: agranulocytosis, anaphylaxis, aplastic anemia, catatonia, congenital
anomalies, CPK increased, deep vein thrombophlebitis, delirium, EKG abnormalities such as QT prolongation; cardiac
arrhythmias including atrial fibrillation, supraventricular tachycardia, ventricular extrasystoles, and rare reports of
ventricular fibrillation and ventricular tachycardia, including torsades de pointes; toxic epidermal necrolysis/Stevens-
Johnson syndrome, erythema multiforme, extrapyramidal symptoms (including dyskinesia and tardive dyskinesia),
angle-closure glaucoma, hemorrhage (including eye and gastrointestinal bleeding), hepatic events (including GGT
elevation; abnormalities of unspecified liver function tests; liver damage, necrosis, or failure; and fatty liver), interstitial
lung disease, involuntary movements, LDH increased, neuroleptic malignant syndrome-like events (including a case of a
10-year-old who may have been taking methylphenidate, was treated and recovered), neutropenia, night sweats,
pancreatitis, pancytopenia, panic, prolactin increased, renal failure, rhabdomyolysis, serotonin syndrome, shock-like
electrical sensations or tinnitus (in some cases, subsequent to the discontinuation of venlafaxine or tapering of dose), and
SIADH (usually in the elderly). Elevated clozapine levels that were temporally associated with adverse events, including
seizures, have been reported following the addition of venlafaxine. Increases in prothrombin time, partial thromboplastin
time, or INR have been reported when venlafaxine was given to patients on warfarin therapy. DRUG ABUSE AND
DEPENDENCE: Effexor XR is not a controlled substance. Evaluate patients carefully for history of drug abuse and observe
such patients closely for signs of misuse or abuse. OVERDOSAGE: The most commonly reported events in overdosage
include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, seizures, and
vomiting. Electrocardiogram changes (eg, prolongation of QT interval, bundle branch block, QRS prolongation), ventricular
tachycardia, bradycardia, hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin syndrome, and death have been
reported. Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk
of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic
antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher pre-existing burden
of suicide risk factors than SSRI-treated patients. The extent to which the finding of an increased risk of fatal outcomes
can be attributed to the toxicity of venlafaxine in overdosage as opposed to some characteristic(s) of venlafaxine-treated
patients is not clear. Treatment should consist of those general measures employed in the management of overdosage
with any antidepressant. Ensure an adequate airway, oxygenation and ventilation. Monitor cardiac rhythm and vital signs.
General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric
lavage with a large bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed
soon after ingestion or in symptomatic patients. Activated charcoal should be administered. Due to the large volume of
distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit.
No specific antidotes for venlafaxine are known. In managing overdosage, consider the possibility of multiple drug
involvement. Consider contacting a poison control center for additional information on the treatment of overdose.
Telephone numbers for certified poison control centers are listed in the Physicians’ Desk Reference® (PDR). DOSAGE AND
ADMINISTRATION: Consult full prescribing information for dosing instructions. Switching Patients to or From an
MAOI—At least 14 days should elapse between discontinuation of an MAOI and initiation of therapy with Effexor XR. 
At least 7 days should be allowed after stopping Effexor XR before starting an MAOI (see CONTRAINDICATIONS
and WARNINGS). 
This brief summary is based on Effexor XR, Prescribing Information W10404C036 ET01, revised February 2008.
© 2008, Wyeth Pharmaceuticals Inc., Philadelphia, PA 19101 231275-01
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However, the limited studies that are 
available suggest a safety profi le similar 
to that of combination OCs with compa-
rable hormone formulations. 
WHOMEC suggests that the guide-
lines for combination OCs also should 
apply to the patch and the ring. Women 
shouldn’t use these contraceptive meth-
ods if they have a history of VTE or cur-
rent VTE or if they are undergoing major 
surgery that may include prolonged im-
mobilization.10 ■
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The patient’s 
preference should 
determine the 
choice between 
an estrogen-
containing OC and 
the patch or ring 
ing factors. The incidence of VTE in this 
study was 40.8 per 100,000 women-
years among patch users and 18.3 per 
100,000 women-years among users of 
the norgestimate-35 μg EE OC. The 
study reported a more than 2-fold in-
creased risk of VTE in patch users com-
pared to OC users (OR=2.4; 95% CI, 
1.1-5.5; IRR=2.2; 95% CI, 1.3-3.8).3,7
Do the differences between 
studies make a difference?
The 2 studies appear similar in design but 
have 2 major identifi able differences:
•  The fi rst study verifi ed VTE diag-
noses by claims for systemic an-
ticoagulants, whereas the second 
study expanded its analysis by 
performing confi rmatory chart re-
views for VTE diagnoses.
•  The fi rst study included only new 
OC and patch users as of April 1, 
2002, whereas the second study in-
cluded new and experienced users 
of the OC as of April 1, 2002.
The signifi cance of the differences 
in these studies is debatable; the results 
have yielded controversial, confl icting 
evidence.
Safety and tolerability are similar 
for the vaginal ring and OCs
A 1-year, open-label, randomized Phase 
III study of 1030 women compared the 
NuvaRing with a combination OC con-
taining levonorgestrel and 30 μg EE. One 
case of deep venous thrombosis occurred 
in the NuvaRing group. 
In reviewing the data, the authors 
concluded that the NuvaRing demon-
strated comparable safety and tolerabil-
ity to the OC.8 NuvaRing users experi-
enced similar side effects compared with 
OC users.9
Recommendations
The World Health Organization Medi-
cal Eligibility Criteria for Contraceptive 
Use (WHOMEC) reports that long-term 
safety data for the estrogen-progestin 
contraceptive patch are not available.10 
VTE risk
685_JFP1008   685 9/18/08   10:50:44 AM
